Brief report: A phase II "window-of-opportunity" frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study

Journal of Thoracic Oncology

Volumn 7, Issue 5, 2012, Pages 919-922

  Reungwetwattana, Thanyanan ^a,b   Molina, Julian R ^a   Mandrekar, Sumithra J ^a   Allen Ziegler, Katie ^a   Rowland, Kendrith M ^c   Reuter, Nicholas F ^d   Luyun, Ronnie F ^c   Dy, Grace K ^e   Marks, Randolph S ^a   Schild, Steven E ^f   Jett, James R ^g   Adjei, Alex A ^e  

^a MAYO CLINIC CANCER CENTER   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Carle Clinic Cancer Center   (United States)

^d CentraCare Coborn Cancer Center   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f MAYO CLINIC   (United States)

^g DEPARTMENT OF MEDICINE   (United States)

Author keywords

Advanced non small cell lung carcinoma; MTOR inhibitors; Temsirolimus; Window of opportunity

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN; PROTEIN KINASE B; S6 KINASE; TEMSIROLIMUS;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOXIA; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN EXFOLIATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 84862133526     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824de0d6     Document Type: Article

References (15)

1. Scagliotti GV, De Marinis F, Rinaldi M, et al.; Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20: 4285-4291.
2. Cappuzzo F, Ciuleanu T, Stelmakh L, et al.; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
3. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
4. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8:187-198.
5. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 1998;95:1432-1437.
6. Hudes G, Carducci M, Tomczak P, et al.; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281.
7. Motzer RJ, Escudier B, Oudard S, et al.; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-456.
8. Galanis E, Buckner JC, Maurer MJ, et al.; North Central Cancer Treatment Group. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005;23:5294-5304.
9. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-151.
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
11. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
12. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537.
13. Hidalgo M, Buckner JC, Erlichman C, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006;12:5755-5763.
14. Soria JC, Shepherd FA, Douillard JY, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009;20:1674-1681.
15. Forgacs E, Biesterveld EJ, Sekido Y, et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 1998;17:1557-1565.